Regulation of Androgen Receptor Conformation

雄激素受体构象的调节

• 批准号: 7152772
• 负责人: JEREMY O JONES
• 金额: $ 4.6万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7152772
• 关键词: actins; androgen receptor; androgens; carcinoma; cell line; conformation; library; ligands; neoplastic cell; nuclear receptors; prostate; prostate neoplasms; reporter genes; small molecule

DESCRIPTION (provided by applicant): The androgen receptor (AR) is a nuclear receptor that is the primary therapeutic target of prostate cancer (CaP). This grant concerns characterization of a cellular pathway that regulates AR activity, which could produce new therapeutic targets, and the application of a novel screening strategy to identify small molecules that inhibit AR function. We hypothesize that the Rho/ROCK/LIM kinase (RRL) pathway regulates AR activity through alterations in the actin cytoskeleton. I will use prostate carcinoma lines that stably express native and fluorescently-labeled AR to determine how the RRL pathway influences the folding, dimerization, nuclear import, and transcriptional activity of AR. We also hypothesize that compounds that inhibit AR ligand-induced conformational change may reveal novel anti-androgens that would be missed by traditional screens for AR inhibitors. I will use a high-throughput FRET assay to screen three collections of biologically active small molecules for compounds that inhibit AR ligand-induced conformational change. The most effective inhibitors will be examined in detailed secondary analyses to determine their effect on AR nuclear transport, dimerization, native AR-responsive transcription, and proliferation of prostate cancer cells.

描述（由申请人提供）：雄激素受体（AR）是一种核受体，是前列腺癌（CaP）的主要治疗靶点。该资助涉及调节 AR 活性的细胞途径的表征，该途径可以产生新的治疗靶点，以及应用新的筛选策略来识别抑制 AR 功能的小分子。我们假设 Rho/ROCK/LIM 激酶 (RRL) 通路通过改变肌动蛋白细胞骨架来调节 AR 活性。我将使用稳定表达天然和荧光标记的 AR 的前列腺癌细胞系来确定 RRL 通路如何影响 AR 的折叠、二聚化、核输入和转录活性。我们还假设，抑制 AR 配体诱导的构象变化的化合物可能会揭示传统 AR 抑制剂筛选中可能漏掉的新型抗雄激素。我将使用高通量 FRET 测定来筛选三个生物活性小分子集合，以寻找抑制 AR 配体诱导的构象变化的化合物。最有效的抑制剂将在详细的二次分析中进行检查，以确定它们对 AR 核转运、二聚化、天然 AR 响应转录和前列腺癌细胞增殖的影响。